<?xml version="1.0" encoding="UTF-8"?>

<PlanDefinition xmlns="http://hl7.org/fhir">
  <id value="IMMZD2DTMeaslesSupplementary"/>
  <meta>
    <profile value="http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-recommendationdefinition"/>
    <profile value="http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-shareableplandefinition"/>
    <profile value="http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-publishableplandefinition"/>
  </meta>
  <text>
    <status value="extensions"/><div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: PlanDefinition </b><a name="IMMZD2DTMeaslesSupplementary"> </a><a name="hcIMMZD2DTMeaslesSupplementary"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">ResourcePlanDefinition &quot;IMMZD2DTMeaslesSupplementary&quot; </p><p style="margin-bottom: 0px">Profiles: <a href="https://build.fhir.org/ig/HL7/cqf-recommendations/StructureDefinition-cpg-recommendationdefinition.html">CPG Recommendation Definition</a>, <a href="http://hl7.org/fhir/uv/crmi/STU1/StructureDefinition-crmi-shareableplandefinition.html">CRMI Shareable PlanDefinition</a>, <a href="http://hl7.org/fhir/uv/crmi/STU1/StructureDefinition-crmi-publishableplandefinition.html">CRMI Publishable PlanDefinition</a></p></div><p><b>CQF Knowledge capability</b>: computable</p><p><b>url</b>: <code>http://smart.who.int/immunizations-measles/PlanDefinition/IMMZD2DTMeaslesSupplementary</code></p><p><b>version</b>: 0.1.0</p><p><b>name</b>: IMMZD2DTMeaslesSupplementary</p><p><b>title</b>: IMMZ.D2.DT.Measles MCV Dose 0</p><p><b>type</b>: ECA Rule <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="http://terminology.hl7.org/5.5.0/CodeSystem-plan-definition-type.html">PlanDefinitionType</a>#eca-rule)</span></p><p><b>status</b>: draft</p><p><b>experimental</b>: true</p><p><b>date</b>: 2024-06-07 12:26:37+0000</p><p><b>publisher</b>: WHO</p><p><b>contact</b>: WHO: <a href="http://who.int">http://who.int</a></p><p><b>description</b>: If the child or patient has not been given a supplementary dose</p><h3>RelatedArtifacts</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Citation</b></td></tr><tr><td style="display: none">*</td><td>citation</td><td>WHO recommendations for routine immunization - summary tables (March 2023)</td></tr></table><p><b>library</b>: <a href="Library-IMMZD2DTMeaslesSupplementaryLogic.html">IMMZD2DTMeaslesSupplementaryLogic</a></p><blockquote><p><b>action</b></p><p><b>title</b>: Immunize patient for Measles</p><blockquote><p><b>condition</b></p><p><b>kind</b>: applicability</p><h3>Expressions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Language</b></td><td><b>Expression</b></td></tr><tr><td style="display: none">*</td><td>text/cql-identifier</td><td>Measles Routine Immunization Schedule Complete</td></tr></table></blockquote><blockquote><p><b>action</b></p><p><b>CPG Rationale Extension</b>: An additional dose of MCV should be administered to HIV-infected children receiving HAART following immune reconstitution. If CD4+ T lymphocyte counts are monitored, an additional dose of MCV should be administered when immune reconstitution has been achieved, e.g. when the CD4+ T lymphocyte count reaches 20–25%. Where CD4+ T lymphocyte monitoring is not available, children should receive an additional dose of MCV 6–12 months after initiation of HAART.&lt;br/&gt;As a general rule, live vaccines should be given either simultaneously or at intervals of 4 weeks. An exception to this rule is OPV, which can be given at any time before or after measles vaccination without interference in the response to either vaccine</p><p><b>title</b>: Consider supplementary dose</p><blockquote><p><b>condition</b></p></blockquote><blockquote><p><b>action</b></p></blockquote><blockquote><p><b>action</b></p></blockquote></blockquote><blockquote><p><b>action</b></p><p><b>title</b>: Supplementary Dose Administered</p><p><b>description</b>: Measles immunization schedule is complete. Measles supplementary dose was administered.</p><blockquote><p><b>condition</b></p></blockquote></blockquote></blockquote></div>
  </text>
  <extension url="http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability">
    <valueCode value="computable"/>
  </extension>
  <url value="http://smart.who.int/immunizations-measles/PlanDefinition/IMMZD2DTMeaslesSupplementary"/>
  <version value="0.1.0"/>
  <name value="IMMZD2DTMeaslesSupplementary"/>
  <title value="IMMZ.D2.DT.Measles MCV Dose 0"/>
  <type>
    <coding>
      <system value="http://terminology.hl7.org/CodeSystem/plan-definition-type"/>
      <code value="eca-rule"/>
    </coding>
  </type>
  <status value="draft"/>
  <experimental value="true"/>
  <date value="2024-06-07T12:26:37+00:00"/>
  <publisher value="WHO"/>
  <contact>
    <name value="WHO"/>
    <telecom>
      <system value="url"/>
      <value value="http://who.int"/>
    </telecom>
  </contact>
  <description value="If the child or patient has not been given a supplementary dose"/>
  <relatedArtifact>
    <type value="citation"/>
    <citation value="WHO recommendations for routine immunization - summary tables (March 2023)"/>
  </relatedArtifact>
  <library value="http://smart.who.int/immunizations-measles/Library/IMMZD2DTMeaslesSupplementaryLogic"/>
  <action>
    <title value="Immunize patient for Measles"/>
    <condition>
      <kind value="applicability"/>
      <expression>
        <language value="text/cql-identifier"/>
        <expression value="Measles Routine Immunization Schedule Complete"/>
      </expression>
    </condition>
    <action>
      <extension url="http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-rationale">
        <valueMarkdown value="An additional dose of MCV should be administered to HIV-infected children receiving HAART following immune reconstitution. If CD4+ T lymphocyte counts are monitored, an additional dose of MCV should be administered when immune reconstitution has been achieved, e.g. when the CD4+ T lymphocyte count reaches 20–25%. Where CD4+ T lymphocyte monitoring is not available, children should receive an additional dose of MCV 6–12 months after initiation of HAART.&lt;br/&gt;As a general rule, live vaccines should be given either simultaneously or at intervals of 4 weeks. An exception to this rule is OPV, which can be given at any time before or after measles vaccination without interference in the response to either vaccine"/>
      </extension>
      <title value="Consider supplementary dose"/>
      <condition>
        <kind value="applicability"/>
        <expression>
          <language value="text/cql-identifier"/>
          <expression value="No Supplementary Dose Administered"/>
        </expression>
      </condition>
      <action>
        <title value="Last Live Vaccine Administered Within 4 Weeks"/>
        <description value="Should not vaccinate client for measles supplementary dose as live vaccine was administered in the last 4 weeks. Check for any vaccines due, and inform the caregiver of when to come back for supplementary dose."/>
        <condition>
          <kind value="applicability"/>
          <expression>
            <language value="text/cql-identifier"/>
            <expression value="Last Live Vaccine Administered Within 4 Weeks"/>
          </expression>
        </condition>
      </action>
      <action>
        <title value="Provide Measles Vaccine"/>
        <description value="May vaccinate client for measles supplementary dose as supplementary dose was not administered, measles routine immunization schedule is complete and no live vaccine administered in the last 4 weeks. Check if one of the measles supplementary dose specific scenarios is applicable."/>
        <condition>
          <kind value="applicability"/>
          <expression>
            <language value="text/cql-identifier"/>
            <expression value="Client Is Due For Supplementary Dose"/>
          </expression>
        </condition>
        <definitionCanonical value="http://smart.who.int/immunizations-measles/ActivityDefinition/IMMZD2DTMeaslesMR"/>
        <dynamicValue>
          <path value="dispenseRequest.validityPeriod.start"/>
          <expression>
            <description value="Due date of the dose"/>
            <language value="text/cql-identifier"/>
            <expression value="MCV Supplementary Schedule Date"/>
          </expression>
        </dynamicValue>
        <dynamicValue>
          <path value="dispenseRequest.validityPeriod.end"/>
          <expression>
            <description value="Expiration date for MCV dose"/>
            <language value="text/cql-identifier"/>
            <expression value="MCV Supplementary Expiration Date"/>
          </expression>
        </dynamicValue>
      </action>
    </action>
    <action>
      <title value="Supplementary Dose Administered"/>
      <description value="Measles immunization schedule is complete. Measles supplementary dose was administered."/>
      <condition>
        <kind value="applicability"/>
        <expression>
          <language value="text/cql-identifier"/>
          <expression value="Supplementary Dose Administered"/>
        </expression>
      </condition>
    </action>
  </action>
</PlanDefinition>